gamma-aminobutyric acid has been researched along with Chronic Inflammatory Demyelinating Polyradiculoneuropathy in 1 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Healthcare costs for CIDP patients are substantial, with a large burden in pharmacy usage." | 1.40 | Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy. ( Bromberg, MB; Guptill, JT; Krueger, A; Sanders, DB; Sharma, BK; Thompson, AR; Zhu, L, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guptill, JT | 1 |
| Bromberg, MB | 1 |
| Zhu, L | 1 |
| Sharma, BK | 1 |
| Thompson, AR | 1 |
| Krueger, A | 1 |
| Sanders, DB | 1 |
1 other study available for gamma-aminobutyric acid and Chronic Inflammatory Demyelinating Polyradiculoneuropathy
| Article | Year |
|---|---|
Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy.
Topics: Adolescent; Adult; Aged; Algorithms; Amines; Analgesics; Anti-Inflammatory Agents; Comorbidity; Cost | 2014 |